A validated algorithm to identify recurrence of bladder cancer: a register-based study in Denmark. 2018

Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
Research Centre for Cancer Diagnosis in Primary Care (CaP), Research Unit for General Practice, Department of Public Health, Aarhus University, 8000 Aarhus C, Denmark, linda.rasmussen@ph.au.dk.

OBJECTIVE Recurrence of cancer is not routinely registered in the national registers in Denmark. The aim of this study was to develop and validate a register-based algorithm to identify patients diagnosed with recurrence of invasive bladder cancer (BC). METHODS We performed a cohort study based on data from Danish national health registers. Diagnosis codes and procedural codes in the Danish National Patient Register and Systematized Nomenclature of Medicine codes in the Danish National Pathology Register were used as indicators of cancer recurrence. Status and date of recurrence as registered in the Danish Bladder Cancer Database (DaBlaCa-data) were used as the gold standard of BC recurrence to ascertain the accuracy of the algorithm. RESULTS The algorithm reached a sensitivity of 85% (95% CI: 78-91), a specificity of 90% (95% CI: 79-96), and a positive predictive value of 95% (95% CI: 89-98). The algorithm demonstrated superior performance in patients undergoing cystectomy compared to patients undergoing radiotherapy as primary BC treatment. The concordance correlation coefficient for the agreement between the recurrence dates generated by the algorithm and the gold standard was 0.96 (95% CI: 0.95-0.98), and the estimated date was set within 90 days of the gold standard date for 90% of patients. CONCLUSIONS The proposed algorithm to identify patients diagnosed with BC recurrence from Danish national registries showed excellent performance in terms of ascertaining occurrence and the timing of BC recurrence.

UI MeSH Term Description Entries

Related Publications

Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
May 2015, International journal of cancer,
Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
April 2015, Annals of epidemiology,
Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
October 2018, Danish medical journal,
Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
January 2023, Clinical epidemiology,
Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
July 1990, British journal of industrial medicine,
Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
December 2022, BMC public health,
Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
June 2020, Current oncology (Toronto, Ont.),
Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
January 2019, PloS one,
Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
January 2018, Acta neurochirurgica. Supplement,
Linda Aagaard Rasmussen, and Henry Jensen, and Line Flytkjær Virgilsen, and Jørgen Bjerggaard Jensen, and Peter Vedsted
May 2022, Npj mental health research,
Copied contents to your clipboard!